Logo image of OPNT

OPIANT PHARMACEUTICALS INC (OPNT) Stock Fundamental Analysis

NASDAQ:OPNT - Nasdaq - US6837501039 - Common Stock - Currency: USD

20.65  -0.12 (-0.58%)

After market: 20.75 +0.1 (+0.48%)

Fundamental Rating

3

Overall OPNT gets a fundamental rating of 3 out of 10. We evaluated OPNT against 194 industry peers in the Pharmaceuticals industry. The financial health of OPNT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, OPNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OPNT has reported negative net income.
OPNT had a negative operating cash flow in the past year.
OPNT Yearly Net Income VS EBIT VS OCF VS FCFOPNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M -10M -20M

1.2 Ratios

OPNT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPNT Yearly ROA, ROE, ROICOPNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 82.70%, OPNT belongs to the best of the industry, outperforming 89.59% of the companies in the same industry.
OPNT's Gross Margin has declined in the last couple of years.
OPNT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.2%
GM growth 5YN/A
OPNT Yearly Profit, Operating, Gross MarginsOPNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

OPNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPNT has more shares outstanding
The debt/assets ratio for OPNT has been reduced compared to a year ago.
OPNT Yearly Shares OutstandingOPNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 1M 2M 3M 4M
OPNT Yearly Total Debt VS Total AssetsOPNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

OPNT has an Altman-Z score of -1.19. This is a bad value and indicates that OPNT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.19, OPNT is in line with its industry, outperforming 46.61% of the companies in the same industry.
A Debt/Equity ratio of 0.60 indicates that OPNT is somewhat dependend on debt financing.
OPNT has a worse Debt to Equity ratio (0.60) than 67.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -1.19
ROIC/WACCN/A
WACC9%
OPNT Yearly LT Debt VS Equity VS FCFOPNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M 20M 30M 40M

2.3 Liquidity

OPNT has a Current Ratio of 5.48. This indicates that OPNT is financially healthy and has no problem in meeting its short term obligations.
OPNT has a Current ratio of 5.48. This is in the better half of the industry: OPNT outperforms 61.09% of its industry peers.
OPNT has a Quick Ratio of 5.48. This indicates that OPNT is financially healthy and has no problem in meeting its short term obligations.
OPNT's Quick ratio of 5.48 is fine compared to the rest of the industry. OPNT outperforms 61.99% of its industry peers.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48
OPNT Yearly Current Assets VS Current LiabilitesOPNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

OPNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13200.00%.
Looking at the last year, OPNT shows a very negative growth in Revenue. The Revenue has decreased by -49.13% in the last year.
OPNT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.00% yearly.
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-442.86%
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y37%
Sales Q2Q%-98.94%

3.2 Future

OPNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 66.96% yearly.
The Revenue is expected to grow by 17.51% on average over the next years. This is quite good.
EPS Next Y-2455.56%
EPS Next 2Y-255.39%
EPS Next 3Y66.96%
EPS Next 5YN/A
Revenue Next Year-80.95%
Revenue Next 2Y-11.14%
Revenue Next 3Y17.51%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
OPNT Yearly Revenue VS EstimatesOPNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OPNT Yearly EPS VS EstimatesOPNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OPNT. In the last year negative earnings were reported.
Also next year OPNT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPNT Price Earnings VS Forward Price EarningsOPNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPNT Per share dataOPNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as OPNT's earnings are expected to grow with 66.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-255.39%
EPS Next 3Y66.96%

More info and screens

0

5. Dividend

5.1 Amount

OPNT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPIANT PHARMACEUTICALS INC

NASDAQ:OPNT (3/1/2023, 8:00:03 PM)

After market: 20.75 +0.1 (+0.48%)

20.65

-0.12 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.97%
Ins Owner Change0%
Market Cap108.80M
Analysts45.71
Price Target21.42 (3.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-45.98%
Min EPS beat(2)-65.91%
Max EPS beat(2)-26.05%
EPS beat(4)1
Avg EPS beat(4)230.99%
Min EPS beat(4)-162.52%
Max EPS beat(4)1178.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-56.68%
Min Revenue beat(2)-95.37%
Max Revenue beat(2)-17.98%
Revenue beat(4)1
Avg Revenue beat(4)-34.27%
Min Revenue beat(4)-95.37%
Max Revenue beat(4)2.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.33%
PT rev (3m)-2.33%
EPS NQ rev (1m)40.78%
EPS NQ rev (3m)40.78%
EPS NY rev (1m)8.77%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)63.64%
Revenue NQ rev (3m)63.64%
Revenue NY rev (1m)-2.9%
Revenue NY rev (3m)-44.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.87
P/FCF N/A
P/OCF N/A
P/B 5.31
P/tB 5.31
EV/EBITDA N/A
EPS(TTM)-6.55
EYN/A
EPS(NY)-3.4
Fwd EYN/A
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS4.24
BVpS3.89
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.7%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.2%
GM growth 5YN/A
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z -1.19
F-Score2
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)180.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-442.86%
EPS Next Y-2455.56%
EPS Next 2Y-255.39%
EPS Next 3Y66.96%
EPS Next 5YN/A
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y37%
Sales Q2Q%-98.94%
Revenue Next Year-80.95%
Revenue Next 2Y-11.14%
Revenue Next 3Y17.51%
Revenue Next 5YN/A
EBIT growth 1Y-1195.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-347.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-339.4%
OCF growth 3YN/A
OCF growth 5YN/A